<DOC>
	<DOC>NCT00952796</DOC>
	<brief_summary>On the basis of monotherapy for intra-abdominal infection, the investigators are conducting this study to identify the difference of drug efficacy between ampicillin/sulbactam and moxifloxacin.</brief_summary>
	<brief_title>A Comparative Study of Ampicillin/Sulbactam Versus Moxifloxacin in the Treatment of Complicated Intra-abdominal Infections</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Intraabdominal Infections</mesh_term>
	<mesh_term>Sulbactam</mesh_term>
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Fluoroquinolones</mesh_term>
	<mesh_term>Sultamicillin</mesh_term>
	<mesh_term>Ampicillin</mesh_term>
	<mesh_term>Norgestimate, ethinyl estradiol drug combination</mesh_term>
	<criteria>patients diagnosed of complicated intraabdominal infection need surgical treatment patients diagnosed of intraabdominal infection receive nonoperative management patients with known allergic history of fluoroquinolone Severe, life threatening disease with a life expectancy of &lt; 48 h or APS and APACHE scores of &gt; 35</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2009</verification_date>
	<keyword>intra-abdominal infection</keyword>
	<keyword>moxifloxacin</keyword>
	<keyword>ampicillin/sulbactam</keyword>
</DOC>